Abstract

Neuroblastoma is a pediatric cancer of the sympathetic nervous system where MYCN amplification is a key indicator of poor prognosis. However, mechanisms by which MYCN promotes neuroblastoma tumorigenesis are not fully understood. In this study, we analyzed global miRNA and mRNA expression profiles of tissues at different stages of tumorigenesis from TH-MYCN transgenic mice, a model of MYCN-driven neuroblastoma. On the basis of a Bayesian learning network model in which we compared pretumor ganglia from TH-MYCN+/+ mice to age-matched wild-type controls, we devised a predicted miRNA-mRNA interaction network. Among the miRNA-mRNA interactions operating during human neuroblastoma tumorigenesis, we identified miR-204 as a tumor suppressor miRNA that inhibited a subnetwork of oncogenes strongly associated with MYCN-amplified neuroblastoma and poor patient outcome. MYCN bound to the miR-204 promoter and repressed miR-204 transcription. Conversely, miR-204 directly bound MYCN mRNA and repressed MYCN expression. miR-204 overexpression significantly inhibited neuroblastoma cell proliferation in vitro and tumorigenesis in vivo Together, these findings identify novel tumorigenic miRNA gene networks and miR-204 as a tumor suppressor that regulates MYCN expression in neuroblastoma tumorigenesis.Significance: Network modeling of miRNA-mRNA regulatory interactions in a mouse model of neuroblastoma identifies miR-204 as a tumor suppressor and negative regulator of MYCN. Cancer Res; 78(12); 3122-34. ©2018 AACR.

Highlights

  • Neuroblastoma is a pediatric malignancy that derives from the progenitors of the sympathetic nervous system [1]

  • We focus on the novel relationship between miR-204 and MYCN and its relevance to neuroblastoma tumorigenesis

  • To evaluate miRNA/mRNA expression in neuroblastoma, we conducted transcriptomic analyses of ganglion tissues derived from the TH-MYCN transgenic mice

Read more

Summary

Introduction

Neuroblastoma is a pediatric malignancy that derives from the progenitors of the sympathetic nervous system [1]. Neuroblastoma accounts for approximately 15% of pediatric cancer–related deaths, mostly attributed to patients with high-stage disease who relapse despite intensive multimodal. Note: Supplementary data for this article are available at Cancer Research Online (http://cancerres.aacrjournals.org/). C.Y. Ooi and D.R. Carter are the co-first authors of this article.

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call